학술논문
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Document Type
Article
Author
Munir, T.; Moreno, C.; Owen, C.; Follows, G.; Benjamini, O.; Janssens, A.; Levin, M.-D.; Osterborg, A.; Robak, T.; Simkovic, M.; Stevens, D.; Voloshin, S.; Vorobyev, V.; Yagci, M.; Ysebaert, L.; Qi, K.; Qi, Q.; Parisi, L.; Caces, D.B.; Srinivasan, S.; Schuier, N.; Baeten, K.; Howes, A.; Niemann, C.U.; Kater, A.P.
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 20 July 2023, 41(21):3689-3699)
Subject
Language
English
ISSN
15277755
0732183X
0732183X